New downstream regulatory element antagonist modulator gene and polypeptide that is a transcriptional repressor, for identifying antitumor agents

摘要

The DREAM (downstream regulatory element (DRE) antagonist modulator) gene (I) and polypeptide (II), in both native and mutated forms; their use as specific transcriptional silencers of DRE sequences; the use of (II) as a target for identifying new therapeutic compounds and the use as a regulator of CRE-dependent gene expression are new. Independent claims are also included for the following: (1) recombinant vectors containing (I); (2) host cells transformed with the vector of (a); (3) identifying therapeutic agents (A) able to block or activate (II); (4) use of embryonic cells of (2) for creating transgenic animals that have disorders associated with alterations in expression or activity of DREAM; (5) a nucleic acid (III) comprising or containing a 2886 base pair (bp) sequence, representing the complementary sequence to DREAM mRNA; (6) a recombinant vector containing (III); (7) host cells transfected with the vector of (6), with suppressed DREAM expression; and (8) mono- or poly-clonal antibodies (Ab) that recognize (II).